Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients

The antisense oligonucleotide nusinersen was the first drug treatment available for all types of 5q-spinal muscular atrophy (SMA). The dosing regime has been derived from pivotal clinical trials in infants and children. The efficacy of nusinersen in severely affected adult SMA patients is still ques...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmanovic, Alma, Schreiber-Katz, Olivia, Petri, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998943/
https://www.ncbi.nlm.nih.gov/pubmed/33805645
http://dx.doi.org/10.3390/brainsci11030367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998943/
https://www.ncbi.nlm.nih.gov/pubmed/33805645
http://dx.doi.org/10.3390/brainsci11030367

Ejemplares similares